# Acute Decompensated Left Heart Failure â€“ Clinical Call Protocol

**Guidelines Referenced:**  
AHA/ACC/HFSA 2022 Guideline for the Management of Heart Failure, 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

## CARD INTERFACE LAYOUT

### Card 0 â€“ Dynamic Action Card (Node Dependent)

```
ACUTE HEART FAILURE EXACERBATION
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚        IMMEDIATE ORDERS                 â”‚
â”‚                                         â”‚
â”‚ â˜‘ Sit patient upright                   â”‚
â”‚ â˜‘ O2 titrate to SpO2 >92%             â”‚
â”‚ â˜‘ IV access if not present            â”‚
â”‚ â˜‘ STAT: BNP, BMP, troponin            â”‚
â”‚ â˜‘ CXR portable                         â”‚
â”‚ â˜‘ Strict I&O, daily weights           â”‚
â”‚ â˜ Foley if severe                     â”‚
â”‚                                         â”‚
â”‚ BNP: 1,850 pg/mL (â†‘â†‘)                 â”‚
â”‚ Cr: 1.8 mg/dL (baseline 1.2)          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

VOLUME STATUS:
â€¢ JVD to angle of jaw
â€¢ Bilateral rales to mid-lung
â€¢ 2+ pitting edema to knees

ğŸš¨ Consider BiPAP if worsening
```

**Example - Diuretic Management Node:**

```
DIURETIC OPTIMIZATION
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

HOME REGIMEN:
â€¢ Furosemide 40mg PO BID

CURRENT STATUS:
â€¢ Last dose: >24 hours ago
â€¢ Creatinine: 1.8 (â†‘ from 1.2)
â€¢ K: 3.8 mEq/L
â€¢ HCO3: 28 mEq/L

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      IV DIURETIC CALCULATOR             â”‚
â”‚                                         â”‚
â”‚ Acute IV Dose = 2.5 x Home PO           â”‚
â”‚ Home: 80mg/day PO                       â”‚
â”‚ Initial IV: 80mg IV x 1                 â”‚
â”‚                                         â”‚
â”‚ â˜‘ Furosemide 80mg IV NOW               â”‚
â”‚ â˜ Add metolazone 5mg if resistant     â”‚
â”‚ â˜ Consider drip if poor response      â”‚
â”‚                                         â”‚
â”‚ Goal UOP: >100 mL/hr x 2 hrs           â”‚
â”‚ Net negative: 1-2L/day                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

DIURETIC RESISTANCE FLAGS:
â–¡ Poor response to initial dose
â–¡ Cr rising >0.3 mg/dL
â–¡ Significant RV failure
â–¡ Severe hyponatremia

MONITORING PLAN:
â€¢ Strict I&O q2h x 6h
â€¢ BMP in AM
â€¢ Daily weights (same scale)
â€¢ Orthostatics if hypotensive

âš ï¸ Hold ACE-I if Cr â†‘ >30% or K >5.5
```

### Card 1 â€“ Static Assessment/Clinical Profiles

```
HEART FAILURE CLASSIFICATION

TYPES & PHENOTYPES:

HFrEF (EF <40%): Systolic dysfunction, better evidence for therapies  
HFmrEF (EF 40-49%): Mixed, treat like HFrEF  
HFpEF (EF â‰¥50%): Diastolic dysfunction, limited therapies

PRECIPITANTS:
â€¢ ACS/ischemia
â€¢ Arrhythmia (AF w/ RVR)
â€¢ Medication nonadherence (#1)
â€¢ Diet indiscretion, infection, anemia, thyroid disturbance

CLINICAL PROFILES:
â€¢ Warm & Wet: Most common, good perfusion, congestion (diuresis)
â€¢ Cold & Wet: Poor perfusion, congestion (inotropes + diuresis)
â€¢ Cold & Dry: Poor perfusion, no congestion (fluid challenge)
â€¢ Warm & Dry: Stable/compensated

HISTORY:
â€¢ Symptom onset/duration, orthopnea, PND
â€¢ Weight gain/trends, medication compliance, infection screen
```

### Card 2 â€“ Physical Exam, Meds, Orders

```
PHYSICAL EXAM

VOLUME ASSESSMENT:
â€¢ JVD: >10cm = congested
â€¢ Hepatojugular reflux: >4cm = RV failure
â€¢ Edema: Degree, distribution, progression

PERFUSION:
â€¢ Cool extremities, narrow pulse pressure, altered mentation, decreased urine output

KEY MEDICATIONS:

ğŸ’Š DIURETICS:
â€¢ Furosemide: IV 2.5x PO home dose, repeat in 2hr if <100mL/hr UOP
â€¢ Switch to bumetanide/torsemide if poor GI absorption
â€¢ Add metolazone (2.5-5mg PO) if loop resistant
â€¢ Continuous infusion: start at 5-10mg/hr
â€¢ Monitor electrolytes, renal, UOP

ğŸ’Š VASODILATORS:
â€¢ Nitroglycerin (if SBP >110): Start 10-20 mcg/min
â€¢ Nitroprusside for severe HTN/crisis with ICU monitoring

ğŸ’Š GDMT OPTIMIZATION:
â€¢ Continue/adjust beta-blockers (hold/reduce if shock, bradycardic)
â€¢ Hold ACE-I/ARB/ARNI if deterioration or K >5.5
â€¢ Start/continue SGLT2i if not contraindicated

âš ï¸ AVOID: NSAIDs, thiazolidinediones, non-essential fluids
```

## Algorithm Flow

```mermaid
graph TD
    A[Acute HF Present<br/>Assess Volume/Perfusion]
    B{Hemodynamically Stable?}
    C[ICU Transfer<br/>Consider Inotropes]
    D[Warm/Cold & Wet/Dry?]
    E[Advanced HF/MCS Evaluation]
    F{Clinical Profile}
    G[IV Diuretics<br/>2.5x Home Dose]
    H[Gentle Diuresis<br/>Consider Inotrope]
    I[Careful Fluid/HD Monitor]
    J[Optimize GDMT/Prevent Triggers]
    K{Good UOP Response?}
    L[Continue Current/Monitor Lytes]
    M[Double Dose or Add Thiazide]
    N{Still Poor Response?}
    O[Continuous Drip/Ultrafiltration]
    P{Perfusion Improving?}
    Q[Continue Plan/Wean Support]
    R[Inotropes/Adv HF Consult]
    S[Daily Assessment<br/>Transition PO]
    T{Ready for Discharge?}
    U[GDMT Optimized<br/>F/U in 7d]
    V[Continue Diuresis<br/>Address Barriers]

    A --> B
    B -- No --> C --> E
    B -- Yes --> D
    D --> F
    F -- "Warm & Wet" --> G
    F -- "Cold & Wet" --> H
    F -- "Cold & Dry" --> I
    F -- "Warm & Dry" --> J
    G --> K
    H --> P
    I --> P
    K -- Yes --> L
    K -- No --> M
    M --> N
    N -- Yes --> O
    N -- No --> L
    P -- Yes --> Q
    P -- No --> R
    L --> S
    Q --> S
    S --> T
    T -- Yes --> U
    T -- No --> V
```

## Interactive Elements

### Diuretic Response Tracker

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      DIURETIC RESPONSE TRACKER          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Furosemide 80mg IV @ 10:00              â”‚
â”‚                                         â”‚
â”‚ UOP:                                    â”‚
â”‚ 10-11am: 250 mL âœ“                       â”‚
â”‚ 11-12pm: 200 mL âœ“                       â”‚
â”‚ 12-1pm: 150 mL                          â”‚
â”‚ 1-2pm: 75 mL âš ï¸                         â”‚
â”‚                                         â”‚
â”‚ Total Output: 675 mL                    â”‚
â”‚ Net Balance: -425 mL                    â”‚
â”‚ RESPONSE: Suboptimal                    â”‚
â”‚                                         â”‚
â”‚ Recommendations: Double dose to 160mg IVâ”‚
â”‚ Add metolazone 5mg PO                   â”‚
â”‚ Check BMP for renal function            â”‚
â”‚ Consider continuous infusion next        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### GDMT Optimization Checklist

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ GUIDELINE-DIRECTED MEDICAL THERAPY      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ HFrEF (EF 35%) â€“ Current Rx:            â”‚
â”‚ â˜‘ Beta-blocker  (Carvedilol 6.25mg BID) â”‚
â”‚ â˜‘ ACE-I/ARB/ARNI (Lisinopril 10mg QD)   â”‚
â”‚ â˜ MRA pending (K/Cr permitting)         â”‚
â”‚ â˜ SGLT2i (Empagliflozin 10mg QD)        â”‚
â”‚ [CALCULATE DOSES] [PRINT PLAN]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Volume Status Monitor

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚        VOLUME STATUS TRENDS             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Admission: 198 lbs  |  Day 1: 196 lbs  â”‚
â”‚ Day 2: 193 lbs      |  Target: 190 lbs â”‚
â”‚ JVP:   12cm â†’ 8cm   |  Goal: <8cm      â”‚
â”‚ Edema:  2+ â†’ 1+     |  Goal: trace     â”‚
â”‚ Rales: Bilateral â†’ clear                â”‚
â”‚ BNP:   1850 â†’ 520 pg/mL                 â”‚
â”‚ Cr:    1.2 â†’ 1.8 â†’ 1.6                  â”‚
â”‚ [UPDATE] [TREND CHART]                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## VIRTUA VOORHEES HEART FAILURE ADDENDA

- **Inpatient Cardiology Consults:** 24/7 via Transfer Center 856-886-5111.
- **Heart Failure Nursing Protocols:** Strict I&O, daily standard scale weights, nursing documentation of JVP, rales, edema.
- **Pharmacy Support:** GDMT optimization, IV/PO diuretic conversion, SGLT2i initiation.
- **Physical Therapy:** Early mobilization and falls prevention.
- **Quality Metrics:** Time to IV diuretic, net negative fluid goal, discharge follow-up within 7 days.

## REFERENCES

- AHA/ACC/HFSA. 2022 Guideline for the Management of Heart Failure.
- ESC 2021 Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure.

**All steps follow current guideline-directed heart failure management with integrated diuretic resistance tracking, volume status monitoring, and optimization of GDMT.**
